Maze Therapeutics Ownership | Who Owns Maze Therapeutics?
Maze Therapeutics Ownership Summary
Maze Therapeutics is owned by 53.88% institutional investors, 1.88% insiders, and 44.24% retail investors. Trv gp iv is the largest institutional shareholder, holding 13.85% of MAZE shares.
MAZE Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Maze Therapeutics | 53.88% | 1.88% | 44.24% |
| Sector | Healthcare Stocks | 232.20% | 10.74% | -142.94% |
| Industry | Biotech Stocks | 382.11% | 10.55% | -292.66% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Trv gp iv | 6.07M | 13.85% | $157.50M |
| Frazier life sciences management | 4.57M | 10.42% | $118.43M |
| Arch venture management | 4.12M | 9.40% | $106.83M |
| Deep track capital, lp | 3.95M | 9.01% | $102.40M |
| Alphabet | 2.41M | 5.50% | $62.56M |
| Blackrock funding, inc. /de | 2.29M | 5.00% | $94.76M |
| Ah capital management | 1.70M | 3.88% | $44.14M |
| Vanguard group | 1.70M | 3.71% | $70.31M |
| Vr adviser | 1.23M | 2.81% | $31.91M |
| Logos global management lp | 1.23M | 2.80% | $31.82M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Trv gp iv | 6.07M | 57.49% | $157.50M |
| Matrix capital management company, lp | 480.00K | 34.52% | $19.89M |
| Arch venture management | 4.12M | 21.70% | $106.83M |
| Foresite capital management iv | 522.66K | 7.42% | $13.55M |
| Trv gp v | 950.80K | 6.97% | $24.65M |
| Washington university | 280.80K | 5.88% | $11.63M |
| Frazier life sciences management | 4.57M | 3.55% | $118.43M |
| Ah capital management | 1.70M | 3.16% | $44.14M |
| Deep track capital, lp | 3.95M | 2.86% | $102.40M |
| Logos global management lp | 1.23M | 2.85% | $31.82M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Vr adviser | 1.23M | 1.80% | 1.23M |
| Blackrock funding, inc. /de | 2.29M | 0.00% | 971.14K |
| Marshall wace, llp | 777.70K | 0.02% | 758.10K |
| Logos global management lp | 1.23M | 2.85% | 615.39K |
| Arrowmark colorado | 545.13K | 0.26% | 545.13K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Foresite capital management iv | 522.66K | 7.42% | -1.59M |
| Matrix capital management company, lp | 480.00K | 34.52% | -1.17M |
| Foresite capital management v | 86.29K | 2.06% | -258.90K |
| Affinity asset advisors | - | - | -250.00K |
| Sphera funds management | 154.34K | 0.84% | -202.11K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Vr adviser | 1.23M | 1.80% | 1.23M | $31.91M |
| Arrowmark colorado | 545.13K | 0.26% | 545.13K | $14.14M |
| Mass general brigham | 239.99K | 1.23% | 239.99K | $9.94B |
| Parkman healthcare partners | 200.00K | 0.54% | 200.00K | $5.19M |
| Goldman sachs group | 114.45K | 0.00% | 114.45K | $4.74M |
Sold Out
| Holder | Change |
|---|---|
| Srs capital advisors | -307.00 |
| Comerica bank | -636.00 |
| Corebridge financial | -4.33K |
| Engineers gate manager lp | -10.21K |
| Davidson kempner capital management lp | -13.67K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 75 | -20.21% | 24,665,288 | -42.60% | 53 | 0.56% | 57 | -8.06% | 9 | -40.00% |
| Sep 30, 2025 | 49 | -33.78% | 17,110,255 | -55.94% | 39 | 0.50% | 34 | -19.05% | 7 | -46.15% |
| Jun 30, 2025 | 74 | 15.63% | 38,836,437 | 8.98% | 88 | 0.57% | 42 | -34.38% | 13 | - |
| Mar 31, 2025 | 67 | - | 40,037,113 | - | 139 | - | 67 | - | - | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 02, 2026 | Bernstein Harold | President, R&D & CMO | Sell | $4.72K |
| Feb 02, 2026 | Bernstein Harold | President, R&D & CMO | Sell | $275.27K |
| Feb 02, 2026 | Bernstein Harold | President, R&D & CMO | Sell | $26.52K |
| Feb 02, 2026 | Bernstein Harold | President, R&D & CMO | Sell | $383.82K |
| Feb 02, 2026 | Bachrodt Amy | SVP, Finance | Sell | $8.83K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 18 |
| 2025 Q4 | - | 8 |
| 2025 Q3 | - | 1 |
MAZE Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools